Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Drugmaker Clinigen agrees to Triton's GBP1.2 billion takeover bid

Wed, 08th Dec 2021 11:56

(Alliance News) - Clinigen Group PLC has accepted a GBP1.2 billion takeover offer from Triton Investment Management Ltd, the two companies confirmed on Wednesday, valuing the company at GBP1.2 billion.

London-based private equity firm Triton will pay 883 pence per share in cash for Clinigen. Shareholders also will receive the already declared final dividend of 5.46p, making the overall value of the deal 888.46p per shares.

Shares in the Staffordshire-based pharmaceuticals and services provider were 10% higher at 900.00 pence on Wednesday morning in London. Last Thursday, Clinigen shares had spiked 18% to 746.50 after the drugmaker confirmed it was in takeover discussions with Triton.

"Triton has been following Clinigen for a long time and is impressed with the strategy adopted by the Clinigen board and management, creating differentiation through a combination of value propositions across the pharmaceutical product lifecycle which provide global access to medicines. Triton recognises the potential Clinigen holds in growing its offering in the global pharmaceutical ecosystem," Triton said.

Clinigen directors unanimously recommended the offer to shareholders.

Chair Elmar Schnee commented: "The Clinigen board believes this offer represents an exceptional opportunity for Clinigen shareholders to realise value for their investment in cash at a very attractive valuation."

By Will Paige; willpaige@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Jun 2016 11:25

Clinigen's Idis Starts Managed Access Programme For Horizon's Ravicti

Read more
14 Jun 2016 07:50

Clinigen's Idis Signs Access Deal For Galen Chemotherapy Drug

Read more
9 Jun 2016 07:40

Clinigen And Basilea To Run Managed Access Programme For Isavuconazole

Read more
10 May 2016 11:09

Clinigen Inks Deal With Cumberland Pharmaceuticals For Ethyol

Read more
5 May 2016 08:42

Clinigen Buys Rights To Bag Presentation Of Foscavir Treatment

Read more
1 Apr 2016 15:01

Dividends Calendar - Week Ahead

Read more
2 Mar 2016 09:31

Clinigen Trading In Line, Buys Totect Drug As First Half Profit Falls

Read more
24 Feb 2016 16:02

Earnings, Trading Statements Calendar - Week Ahead

Read more
19 Jan 2016 09:23

Clinigen Group's acquisitions boost first half growth

(ShareCast News) - Clinigen Group says it has had a solid first half performance, driven by acquisitions and organic growth. The AIM-listed company issued a trading update for the six months to 31 December on Tuesday. It said revenue had risen 116% and it had doubled its gross profit from last year

Read more
19 Jan 2016 07:47

Clinigen First Half Solid With Revenue And Profit Up On Acquisitions

Read more
12 Jan 2016 16:05

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Dec 2015 09:46

BROKER RATINGS SUMMARY: Berenberg Upgrades Meggitt To Buy From Hold

Read more
3 Dec 2015 12:14

Clinigen Signs Managed Access Programme With Sunesis For Vosaroxin

Read more
30 Nov 2015 08:50

Clinigen Starts Managed Access Programme For Takeda's Ixazomib

Read more
24 Nov 2015 09:22

Clinigen Secures Two-Year Renewal On Accord Healthcare Agreement

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.